Blomgren H. Lax I. Näslund I. et al.

Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients.

Acta Oncol. 34: 861-870Lax I. Blomgren H. Larson D. et al.

Extracranial stereotactic radiosurgery of localized targets.

J Radiosurg. 1: 135-148

Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current State and Future Opportunities.

Dig Dis Sci. 64: 1008-1015Boda-Heggemann J. Knopf A.C. Simeonova-Chergou A. et al.

Deep Inspiration Breath Hold-Based Radiation Therapy: A Clinical Review.

Int J Radiat Oncol Biol Phys. 94: 478-492Giraud P. Morvan E. Claude L. et al.

Respiratory gating techniques for optimization of lung cancer radiotherapy.

J Thorac Oncol. 6: 2058-2068Ezzell G.A. Galvin J.M. Low D. et al.

Guidance document on delivery, treatment planning, and clinical implementation of IMRT: report of the IMRT Subcommittee of the AAPM Radiation Therapy Committee.

Med Phys. 30: 2089-2115Xing L. Thorndyke B. Schreibmann E. et al.

Overview of image-guided radiation therapy.

Med Dosim. 31: 91-112Bujold A. Massey C.A. Kim J.J. et al.

Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma.

J Clin Oncol. 31: 1631-1639Culleton S. Jiang H. Haddad C.R. et al.

Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma.

Radiother Oncol. 111: 412-417Lasley F.D. Mannina E.M. Johnson C.S. et al.

Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy.

Pract Radiat Oncol. 5: e443-e449Weiner A.A. Olsen J. Ma D. et al.

Stereotactic body radiotherapy for primary hepatic malignancies - Report of a phase I/II institutional study.

Radiother Oncol. 121: 79-85Feng M. Suresh K. Schipper M.J. et al.

Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial.

JAMA Oncol. 4: 40-47Durand-Labrunie J. Baumann A.S. Ayav A. et al.

Curative Irradiation Treatment of Hepatocellular Carcinoma: A Multicenter Phase 2 Trial.

Int J Radiat Oncol Biol Phys. 107: 116-125Yoon S.M. Kim S.Y. Lim Y.S. et al.

Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial.

Clin Mol Hepatol. 26: 506-515Wahl D.R. Stenmark M.H. Tao Y. et al.

Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma.

J Clin Oncol. 34: 452-459Lee J. Shin I.S. Yoon W.S. et al.

Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: Meta-analyses and a systematic review.

Radiother Oncol. 145: 63-70Cacciola A. Parisi S. Tamburella C. et al.

Stereotactic body radiation therapy and radiofrequency ablation for the treatment of liver metastases: How and when?.

Rep Pract Oncol Radiother. 25: 299-306Eriguchi T. Takeda A. Sanuki N. et al.

Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system.

Int J Radiat Oncol Biol Phys. 85: 1006-1011Barney B.M. Olivier K.R. Macdonald O.K. et al.

Clinical outcomes and dosimetric considerations using stereotactic body radiotherapy for abdominopelvic tumors.

Am J Clin Oncol. 35: 537-542Velec M. Haddad C.R. Craig T. et al.

Predictors of Liver Toxicity Following Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.

Int J Radiat Oncol Biol Phys. 97: 939-946Pan C.C. Kavanagh B.D. Dawson L.A. et al.

Radiation-associated liver injury.

Int J Radiat Oncol Biol Phys. 76: S94-S100Kavanagh B.D. Pan C.C. Dawson L.A. et al.

Radiation dose-volume effects in the stomach and small bowel.

Int J Radiat Oncol Biol Phys. 76: S101-S107Miften M. Vinogradskiy Y. Moiseenko V. et al.

Radiation Dose-Volume Effects for Liver SBRT.

Int J Radiat Oncol Biol Phys. 110: 196-205Tse R.V. Hawkins M. Lockwood G. et al.

Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

J Clin Oncol. 26: 657-664Nabavizadeh N. Waller J.G. Fain R. et al.

Safety and Efficacy of Accelerated Hypofractionation and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients With Varying Degrees of Hepatic Impairment.

Int J Radiat Oncol Biol Phys. 100: 577-585Bush D.A. Kayali Z. Grove R. et al.

The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial.

Cancer. 117: 3053-3059Hong T.S. Wo J.Y. Yeap B.Y. et al.

Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

J Clin Oncol. 34: 460-468Kasuya G. Kato H. Yasuda S. et al.

Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials.

Cancer. 123: 3955-3965Fukumitsu N. Sugahara S. Nakayama H. et al.

A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma.

Int J Radiat Oncol Biol Phys. 74: 831-836Witt J.S. Rosenberg S.A. Bassetti M.F.

MRI-guided adaptive radiotherapy for liver tumours: visualising the future.

Lancet Oncol. 21: e74-e82Bohoudi O. Bruynzeel A.M.E. Senan S. et al.

Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer.

Radiother Oncol. 125: 439-444Green O.L. Henke L.E. Hugo G.D.

Practical Clinical Workflows for Online and Offline Adaptive Radiation Therapy.

Semin Radiat Oncol. 29: 219-227Mittauer K. Paliwal B. Hill P. et al.

A New Era of Image Guidance with Magnetic Resonance-guided Radiation Therapy for Abdominal and Thoracic Malignancies.

Cureus. 10: e2422Rosenberg S.A. Henke L.E. Shaverdian N. et al.

A Multi-Institutional Experience of MR-Guided Liver Stereotactic Body Radiation Therapy.

Adv Radiat Oncol. 4: 142-149Feldman A.M. Modh A. Glide-Hurst C. et al.

Real-time Magnetic Resonance-guided Liver Stereotactic Body Radiation Therapy: An Institutional Report Using a Magnetic Resonance-Linac System.

Cureus. 11: e5774Henke L.E. Olsen J.R. Contreras J.A. et al.

Stereotactic MR-Guided Online Adaptive Radiation Therapy (SMART) for Ultracentral Thorax Malignancies: Results of a Phase 1 Trial.

Adv Radiat Oncol. 4: 201-209Oderinde O.M. Shirvani S.M. Olcott P.D. et al.

The technical design and concept of a PET/CT linac for biology-guided radiotherapy.

Clin Transl Radiat Oncol. 29: 106-112

Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy.

Radiat Res. 147: 541-550

BGRT: biologically guided radiation therapy-the future is fast approaching.

Med Phys. 34: 3739-3751Xiang L. Tang S. Ahmad M. et al.

High Resolution X-ray-Induced Acoustic Tomography.

Sci Rep. 6: 26118Lei H. Zhang W. Oraiqat I. et al.

Toward in vivo dosimetry in external beam radiotherapy using x-ray acoustic computed tomography: A soft-tissue phantom study validation.

Med Phys. https://doi.org/10.1002/mp.13070Oraiqat I. Zhang W. Litzenberg D. et al.

An ionizing radiation acoustic imaging (iRAI) technique for real-time dosimetric measurements for FLASH radiotherapy.

Med Phys. 47: 5090-5101Ba Sunbul N.H. Zhang W. Oraiqat I. et al.

A simulation study of ionizing radiation acoustic imaging (iRAI) as a real-time dosimetric technique for ultra-high dose rate radiotherapy (UHDR-RT).

Med Phys. 48: 6137-6151Hickling S. Leger P. El Naqa I.

On the Detectability of Acoustic Waves Induced Following Irradiation by a Radiotherapy Linear Accelerator.

IEEE Trans Ultrason Ferroelectr Freq Control. 63: 683-690Hickling S. Lei H. Hobson M. et al.

Experimental evaluation of x-ray acoustic computed tomography for radiotherapy dosimetry applications.

Med Phys. 44: 608-617Hickling S. Xiang L. Jones K.C. et al.

Ionizing radiation-induced acoustics for radiotherapy and diagnostic radiology applications.

Med Phys. 45: e707-e721Jackson W.C. Suresh K. Maurino C. et al.

A mid-treatment break and reassessment maintains tumor control and reduces toxicity in patients with hepatocellular carcinoma treated with stereotactic body radiation therapy.

Radiother Oncol. 141: 101-107Jackson W.C. Tang M. Maurino C. et al.

Individualized Adaptive Radiation Therapy Allows for Safe Treatment of Hepatocellular Carcinoma in Patients With Child-Turcotte-Pugh B Liver Disease.

Int J Radiat Oncol Biol Phys. 109: 212-219Baumann B.C. Wei J. Plastaras J.P. et al.

Stereotactic Body Radiation Therapy (SBRT) for Hepatocellular Carcinoma: High Rates of Local Control With Low Toxicity.

Am J Clin Oncol. 41: 1118-1124Jackson W.C. Hartman H.E. Gharzai L.A. et al.

The Potential for Midtreatment Albumin-Bilirubin (ALBI) Score to Individualize Liver Stereotactic Body Radiation Therapy.

Int J Radiat Oncol Biol Phys. 111: 127-134Anscher M.S. Crocker I.R. Jirtle R.L.

Transforming growth factor-beta 1 expression in irradiated liver.

Radiat Res. 122: 77-85Anscher M.S. Peters W.P. Reisenbichler H. et al.

Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer.

N Engl J Med. 328: 1592-1598Hong T.S. Grassberger C. Yeap B.Y. et al.

Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy.

NPJ Precis Oncol. 2: 22Cuneo K.C. Devasia T. Sun Y. et al.

Serum Levels of Hepatocyte Growth Factor and CD40 Ligand Predict Radiation-Induced Liver Injury.

Transl Oncol. 12: 889-894Küsters S. Tiegs G. Alexopoulou L. et al.

In vivo evidence for a functional role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis.

Eur J Immunol. 27: 2870-2875Heyninck K. Wullaert A. Beyaert R.

Nuclear factor-kappa B plays a central role in tumour necrosis factor-mediated liver disease.

Biochem Pharmacol. 66: 1409-1415

TNFα in liver fibrosis.

Curr Pathobiol Rep. 3: 253-261Cope A.P. Aderka D. Doherty M. et al.

Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases.

Arthritis Rheum. 35: 1160-1169Aderka D. Wysenbeek A. Engelmann H. et al.

Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus.

Arthritis Rheum. 36: 1111-1120Khoury S.J. Orav E.J. Guttmann C.R. et al.

Changes in serum levels of ICAM and TNF-R correlate with disease activity in multiple sclerosis.

Neurology. 53: 758-764Cousins M.M. Devasia T.P. Maurino C.M. et al.

Pretreatment Levels of Soluble Tumor Necrosis Factor Receptor 1 and Hepatocyte Growth Factor Predict Toxicity and Overall Survival After.

J Nucl Med. 63: 882-889Cousins M.M. Morris E. Maurino C. et al.

TNFR1 and the TNFα axis as a targetable mediator of liver injury from stereotactic body radiation therapy.

Transl Oncol. 14: 100950Bierman H.R. Byron R.L. Kelley K.H. et al.

Studies on the blood supply of tumors in man. III. Vascular patterns of the liver by hepatic arteriography in vivo.

J Natl Cancer Inst. 12: 107-131

The blood supply of neoplasms in the liver.

Am J Pathol. 30: 969-977Garin E. Lenoir L. Rolland Y. et al.

Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results.

J Nucl Med. 53: 255-263Salem R. Johnson G.E. Kim E. et al.

Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study.

Hepatology. 74: 2342-2352Lewandowski R.J. Gabr A. Abouchaleh N. et al.

Radiation Segmentectomy: Potential Curative Therapy for Early Hepatocellular Carcinoma.

Radiology. 287: 1050-1058Vouche M. Habib A. Ward T.J. et al.

Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy.

Hepatology. 60: 192-201Riaz A. Gates V.L. Atassi B. et al.

Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization.

Int J Radiat Oncol Biol Phys. 79: 163-171Biederman D.M. Titano J.J. Korff R.A. et al.

Radiation Segmentectomy versus Selective Chemoembolization in the Treatment of Early-Stage Hepatocellular Carcinoma.

J Vasc Interv Radiol. 29: 30-37.e2Padia S.A. Johnson G.E. Horton K.J. et al.

Segmental Yttrium-90 Radioembolization versus Segmental Chemoembolization for Localized Hepatocellular Carcinoma: Results of a Single-Center, Retrospective, Propensity Score-Matched Study.

J Vasc Interv Radiol. 28: 777-785.e1Dewaraja Y.K. Chun S.Y. Srinivasa R.N. et al.

Improved quantitative.

Med Phys. 44: 6364-6376Garin E. Tselikas L. Guiu B. et al.

Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial.

Lancet Gastroenterol Hepatol. 6: 17-29Kappadath S.C. Mikell J. Balagopal A. et al.

Hepatocellular Carcinoma Tumor Dose Response After.

Int J Radiat Oncol Biol Phys. 102: 451-461Wei L. Cui C. Xu J. et al.

Tumor response prediction in.

EJNMMI Phys. 7: 74Luterstein E. Cao M. Lamb J.M. et al.

Clinical Outcomes Using Magnetic Resonance-Guided Stereotactic Body Radiation Therapy in Patients With Locally Advanced Cholangiocarcinoma.

Adv Radiat Oncol. 5: 189-195Boldrini L. Romano A. Mariani S. et al.

MRI-guided stereotactic radiation therapy for hepatocellular carcinoma: a feasible and safe innovative treatment approach.

J Cancer Res Clin Oncol. 147: 2057-2068